GeoVax to Present Corporate Update at Noble Capital Markets Emerging Growth Conference

GeoVax Labs, Inc. announced that Chairman and CEO David Dodd will present a corporate update at Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference on December 3, 2025. The presentation will provide investors with current developments regarding the company's clinical-stage biotechnology programs focused on human vaccines and cancer immunotherapies.

The company's lead clinical program involves GEO-CM04S1, a next-generation COVID-19 vaccine currently undergoing three Phase 2 clinical trials. These trials are evaluating the vaccine as a primary immunization for immunocompromised patients, including those with hematologic cancers, who may not respond adequately to currently authorized COVID-19 vaccines. Additional studies are examining its effectiveness as a booster vaccine in patients with chronic lymphocytic leukemia and as a more robust COVID-19 booster for healthy individuals who previously received mRNA vaccines.

In oncology, GeoVax is advancing Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The company is also developing a vaccine targeting Mpox and smallpox, and based on recent regulatory guidance, anticipates progressing directly to Phase 3 clinical evaluation without conducting Phase 1 and Phase 2 trials.

Investors and guests interested in attending the presentation can register through the conference website at https://www.nobleconference.com using discount code GOVXNOBLECON. A high-definition video webcast of the presentation will be available the following day through Noble Capital Markets' conference website and on Channelchek at https://www.channelchek.com, where it will be archived for 90 days following the event. Senior management will also conduct one-on-one meetings with registered attendees during the conference.

GeoVax maintains a strong intellectual property portfolio supporting its technologies and product candidates, holding worldwide rights for its innovations. The company's presentation at this emerging growth equity conference represents an important opportunity for investors to gain insight into the progress of clinical trials and the potential impact of these medical advancements on patient care, particularly for vulnerable populations who may benefit from more effective vaccine options and cancer treatments.